Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?

ABSTRACT: Our understanding of the immunopathological features of type 1 diabetes (T1D) has greatly improved over the past two decades and has shed light on disease heterogeneity dictated by multiple immune, metabolic, and clinical parameters. This may explain the limited effects of immunotherapies tested so far to durably revert or prevent T1D, for which life-long insulin replacement remains the only therapeutic option. In the era of omics and precision medicine, offering personalized treatment could contribute to turning this tide. Here, we discuss how to structure the selection of the right patient at the right time for the right treatment. This individualized therapeutic approach involves enrolling patients at a defined disease stage depending on the target and mode of action of the selected dru

SUBMITTER: Deligne C 

PROVIDER: S-EPMC9031881 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature